Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

Stock Information for Armata Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit
Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update
Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference
Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023
Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.